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Abstract
Objective It is unknown how sex affects the prevalence of freezing of gait (FOG). We conducted a systematic review and 
meta-analysis to establish the sex-specific prevalence of FOG in persons with Parkinson’s disease (PD). In addition, we 
investigated whether men and women were represented accurately in intervention trials targeting FOG.
Methods We queried the EMBASE and PubMed databases and identified 2637 articles. Of these, 16 epidemiological studies 
were included in the meta-analysis, and 51 intervention studies were included in the comparative analysis.
Results In total, 5702 persons were included in the final meta-analysis of epidemiological studies. The pooled estimate 
of overall FOG prevalence was 43% [95% CI 33–53%]. We found no difference in FOG prevalence between men [44% 
(34–54%)] and women [42% (31–52%)] with PD. However, women were markedly underrepresented in intervention trials 
targeting FOG, with an average proportion of only 29.6% of women in trial populations. The percentage of women included 
in trials was similar across intervention types but differed greatly across geographical regions.
Conclusion Sex is not a predictor of FOG. This could aid clinicians in counseling persons with PD about FOG. Importantly, a 
global effort is needed to include more women into clinical trials. Given the skewed distribution of men and women included 
in intervention trials targeting FOG, caution might be warranted when extrapolating results from FOG trials to women.
Keywords Parkinson · FOG · Freezing of gait · Gender · Prevalence
Introduction
Freezing of gait (FOG) is a common and disabling phenom-
enon in people with Parkinson’s disease (PD). It is character-
ized by brief episodes during which patients experience their 
feet as being “glued to the floor” [1]. Presence of FOG is an 
important predictor of future falls and loss of independence, 
and reduces quality of life of affected individuals [2, 3]. The 
exact mechanisms underlying FOG are not fully understood, 
but several factors seem associated, including longer dis-
ease duration, cognitive decline and presence of depres-
sion or anxiety [4–7]. Interestingly, most video-illustrated 
case reports and case series on FOG display footage of men 
[8–12]. This may suggest that FOG is more common in men 
compared to women. However, it remains unclear whether 
sex affects the prevalence of FOG [13, 14]. Gaining more 
insight into potential sex differences in FOG prevalence 
could aid clinicians in counselling PD patients, as well as 
researchers in selecting an appropriate study population for 
clinical trials targeting FOG. In this systematic review and 
meta-analysis, we report pooled estimates of the sex-specific 
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prevalence of FOG in persons with PD. We also investigate 
whether this sex distribution is adequately reflected in recent 
clinical trials targeting FOG.
Methods
Inclusion criteria
Main selection criteria and methods of analysis were speci-
fied and documented in advance. The systematic review was 
conducted in accordance with the PRISMA statement [15], 
following an a priori protocol (available upon request). The 
criteria for eligibility are reported in Table 1. Key criteria 
for epidemiological studies included: observational cohort- 
or cross-sectional study design, ambulatory, outpatient or 
community-based setting, and a minimum of 100 male and 
female participants with FOG included. Key criteria for 
intervention studies included: intervention studies published 
between June 2014 and December 2019, ambulatory, out-
patient or community-based setting, and a minimum of 10 
participants with FOG included.
Search strategy
In June 2019 the PubMed (NLM) and EMBASE (Elsevier) 
databases were searched. The search strategy was deter-
mined with the help of a medical librarian and was used 
for the selection of both epidemiological studies and inter-
vention studies. “Freezing of gait”, “Parkinson’s disease” 
and related terms were used. Full details of the search 
strategy are available in Appendix e-1. Reference lists of 
included studies were examined for additional relevant 
studies. An update search was conducted in December 
2019, to check for relevant studies that were published 
since the original search.
Study screening and selection
All records were assessed for eligibility by two inde-
pendent reviewers (AT, MM). Any disagreement was 
resolved by a third independent reviewer (JN). Only 
unique nonoverlapping study populations were included. 
Reasons for exclusion of studies were logged through-
out the process. In- and exclusion criteria were spe-
cifically designed to eliminate epidemiological studies 
with a high risk of bias. No formal quality assessment 
took place for the intervention studies, since the focus 
of this review was to investigate the sex distribution 
within the study sample, and not the actual effect of the 
intervention.
Standard protocol approvals, registrations, 
and patient consents
No ethical approval was required for this systematic review 
and meta-analysis. The predefined review protocol was 
submitted to the PROSPERO database (pending).
Table 1  Criteria for eligibility, per arm of the systematic review
PD Parkinson’s disease, FOG freezing of gait, DBS deep brain stimulation
Epidemiological studies Intervention studies
Inclusion criteria Inclusion criteria
 Includes human participants diagnosed with idiopathic PD;  Includes human participants diagnosed with idiopathic PD and 
FOG;
 Includes both male and female participants;  Includes ≥ 10 participants with FOG in the final analysis;
 Includes ≥ 100 participants with FOG in the final analysis;  Reports sex distribution of study participants;
 Reports prevalence of FOG within the cohort;  Published between June 2014 – December 2019;
 Reports sex distribution within the cohort and within FOG subgroup;  Published in English or Dutch
 Observational cohort studies (retrospective or prospective) and cross-sec-
tional studies;
 Ambulatory, outpatient or community-based settings only;
 Published in English or Dutch
Exclusion criteria Exclusion criteria
 Studies that enroll participants who are receiving a particular intervention;  Inpatient or acute care settings;
 Inpatient or other acute care settings;  Interventions specifically targeted to either men, or women (e.g. 
hormonal therapy in women);
 Other studies that cannot be expected to provide generalizable estimates of 
prevalence
 Interventions specifically targeted to a specific subgroup of PD 
patients with FOG (e.g. DBS populations)
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Data extraction
Data extraction was performed by two independent review-
ers (AT, MM). Any discrepancies were resolved by consult-
ing a third reviewer (JN). All data were recorded in a prede-
fined data extraction form. When necessary, corresponding 
authors were contacted to provide missing or additional 
information.
For all included epidemiological studies, the following 
data were extracted: study location, study setting, primary 
outcome, manner of recruitment, criteria used to establish 
presence of FOG, patient characteristics including mean age, 
mean disease duration, and mean (MDS)-UPDRS part III 
scores, total participants included, total male participants 
included, total participants with FOG included, and total 
male participants with FOG included.
For all intervention studies, the following data were 
extracted: study location, intervention type (e.g. physi-
otherapy/cueing, pharmacological), a short summary of the 
intervention, total participants with FOG included, and total 
male participants with FOG included.
Synthesis and statistical analysis
For each epidemiological study, both the overall and the sex-
specific prevalence of FOG were calculated. Overall FOG 
prevalence per study was calculated as follows: (number of 
participants with FOG/total number of participants in the 
study) × 100. Sex-specific prevalence of FOG per study was 
calculated for both men and women as follows: (number of 
men or women included in the FOG subgroup)/(number of 
men or women included in the total sample) × 100.
Meta-analyses were performed to provide pooled esti-
mates of overall FOG prevalence, and FOG prevalence 
among men and women separately. Analyses were per-
formed in Stata (StataCorp. 2019. Stata Statistical Soft-
ware: Release 16. College Station, TX: StataCorp LLC.), 
using the metaprop program for pooling binomial data 
[16]. Additionally, a multivariable meta-regression analy-
sis was performed, to investigate the influence of sex on 
overall FOG prevalence, independently of disease duration 
and -severity. A random effects model was employed for all 
analyses, because of the clinical heterogeneity of included 
studies. The degree of statistical heterogeneity was assessed 
using the I2 index. p values < 0.05 were considered to be 
significant.
For each intervention study, sex distribution of included 
participants was calculated by: (number of men with 
FOG included/total number of participants with FOG 
included) × 100. Studies including < 45% male participants 
were marked as ‘female-predominant’, studies including 
45–55% male participants were marked as ‘neutral’, and 
studies including > 55% male participants were marked as 
‘male-predominant’. Studies were categorized per interven-
tion type, and geographical region.
Data availability




In total, 2637 deduplicated records were retrieved from 
PubMed and EMBASE. After title and abstract screening, 
the full text of 178 articles was evaluated, after which 16 
epidemiological reports were included in the final meta-
analysis. In addition, 51 recent intervention studies on FOG 
were included for comparative analyses. Figure 1 shows a 
flowchart of the screening and selection process. Conference 
abstracts were screened during the process, but excluded 
because (1) the information provided was too limited to 
determine whether the study met all the pre-defined inclu-
sion criteria, or (2) a published final full article was also 
available, and part of the search result. Corresponding 
authors had to be contacted for additional information in 
ten cases. All queries concerned missing patient character-
istics data for subgroup analyses (e.g. mean age or UPDRS 
motor score of the total cohort). One corresponding author 
responded. After three months, the remaining nine queries 
were marked as missing data.
Estimation of sex‑specific prevalence of FOG
The 16 epidemiological studies in the final meta-analysis 
included a total of 5702 persons with PD. The average num-
ber of participants per study was 356 (range 100–990). Five 
studies included more than 500 participants. The average 
percentage of men included in the studies was 57.5% (range 
41.1–66.1%). The mean disease duration of included par-
ticipants was 7.0 years (range 4.8–12.1). Studies were con-
ducted in Europe (n = 6), Asia–Pacific (n = 6), and North 
America (n = 4). In most studies, presence of FOG was iden-
tified using item 3 of the Freezing of Gait Questionnaire [17] 
(n = 7). In other studies, item 14 of the UPDRS part II [18] 
(n = 3), item 1 of the New Freezing of Gait Questionnaire 
[19] (n = 1), and other self-reported questionnaires (n = 3) 
were used to establish presence of FOG. In one study the 
presence of FOG was retrospectively extracted from medi-
cal records. One study did not report their method used to 
identify the presence of FOG. The full extracted study data 
are available in Online Appendix e-2.
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Figure 2 presents the forest plots of pooled estimates of 
overall prevalence of FOG, as well as sex-specific preva-
lence of FOG. The pooled estimate of overall prevalence of 
FOG was 43% (95% CI 33–53%). The pooled estimate of 
FOG prevalence for men was 44% (95% CI 34–54%), and 
for women 42% (95% CI 31–52%). Included studies were 
highly heterogeneous (I2> 97%).
A multivariate random effects meta-regression did not 
demonstrate a relationship between sex and overall FOG 
prevalence (p = 0.333).
Sex distribution in recent intervention trials on FOG
A total of 51 intervention studies were included in the com-
parative analysis. Included studies were categorized per 
intervention type: physiotherapy/cueing (n = 32), non-inva-
sive brain stimulation (n = 9), pharmacological treatment 
(n = 5), neurosurgical intervention (n = 4), or cognitive train-
ing (n = 1). Most studies were performed in Europe (n = 23), 
followed by Asia (n = 10), and North America (n = 9).
The overall sex distribution of included participants is 
presented in Fig. 3. Out of 51 intervention studies, a mere 9 
(17.6%) trials included a neutral sample in terms of sex dis-
tribution, whereas 40 (78.4%) trials were male-predominant. 
On average, 29.6% (range 0–56.7%) of study participants 
were women. The percentage of women included in trials 
was similar across intervention types: physiotherapy/cueing 
(mean: 29%, range 0–57%), non-invasive brain stimulation 
(mean: 34%, range 15–50%), pharmacological treatment 
(mean: 30%, range 14–52%), and neurosurgical interven-
tions (mean: 29%, range 8–46%). Moreover, Fig. 3 demon-
strates the results stratified by geographical location, where 
a marked difference in the recruitment of women is appar-
ent across regions. Notably, all trials performed in North 
America (n = 9) were male-predominant.
Discussion
Our main aim was to establish the sex-specific prevalence of 
freezing of gait (FOG) in PD. We also investigated whether 
recent intervention trials targeting FOG portrayed an accu-
rate representation of the FOG disease population in terms 
of sex distribution. We found no difference in FOG preva-
lence between men and women with PD. However, women 
were markedly underrepresented in recent intervention trials 
targeting FOG.
The absent sex difference in FOG prevalence contradicts 
previous findings in a large cohort of 6,620 patients, where 
male sex was identified as a predictor of FOG in PD (OR 
1.19 [1.04–1.35]) [13]. This study by Macht et al. was not 
included in the present meta-analysis because it did not 
report the sex distribution within the FOG subgroup. An 
obvious strength of their study was the large number of 

















Records retrieved through database search (Pubmed, Embase)
(n=4020)
Remaining records aer 1383 duplicates removed 
(n=2637)
Remaining records aer 
tle and abstract screening
(n=116)
Studies included in analysis 
aer full-text screening
(n=51)
Remaining records aer 
tle and abstract screening
(n=178)




- Not relevant (n=1444) 
- Study design (n= 998)
- Language (n= 17)
Excluded (n=2521)
- Published >5 years ago (n=1476)
- Not relevant (n=863) 
- Study design (n=114)
- Included <10 subjects (n=68)
Excluded (n=65)
- No gender-specific informaon (n=13)
- Populaon not representave (n=52)
Excluded (n=162)
- No full arcle text (n=86)
- No gender-specific informaon (n=62)
- Populaon not representave (n=14)
Fig. 1  PRISMA flow diagram of the screening and selection process. No full article text (e.g. conference abstracts); Population not representa-
tive (e.g. preselected groups such as persons who had all received deep brain stimulation prior to FOG onset)
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respondents, and the fact that the included men and women 
were similar in terms of age and disease duration–the latter 
features are well-known determinants of FOG prevalence 
[20]. However, the outcomes of the study by Macht et al. 
should be interpreted with some caution, for various reasons. 
First, the study was originally designed to investigate the 
predictors of sudden onset of sleepiness, and the observed 
FOG prevalence resulted from post hoc analyses. Second, 
the definition of freezing that was used differed from vali-
dated self-reported questionnaires, such as the NFOG-Q 
and FOG-Q. Specifically, their definition was not limited 
to FOG, but encompassed freezing in a broader sense, also 
including upper limb freezing and freezing of speech. Third, 
the five possible answer options as to how often respond-
ents experienced freezing were dichotomized. In doing so, 
respondents who reported freezing less than twice a month 
were not included in the freezing subgroup, which might 
have affected the prevalence estimate. In the present meta-
analysis, we were able to provide a similar sample size, with 
enough power to study potential sex differences in FOG 
prevalence among people with PD, by pooling data from a 
myriad of smaller studies.
Study Group (n) Esmated prevalence of freezing of gait % [LCI – UCI] % Weight
Kim et al. (2018) Overall (325)
F (150)
M (175)
8 [6 – 12]
7 [4 – 12]




Burn et al. (2012) Overall (513)
F (179)
M (334)
15 [12 – 18]
12 [8 – 17]




Factor et al. (2011) Overall (499)
F (190)
M (309)
16 [13 – 20]
19 [14 – 25]




Lieberman et al. (2006) Overall (n=109)
F (37)
M (72)
27 [19 – 36]
27 [15 – 43]




Giladi et al. (1992) Overall (990)
F (396)
M (594)
32 [29 – 35]
32 [28 – 37]




Perez-Lloret et al. (2014) Overall (672)
F (291)
M (381)
38 [35 – 42]
31 [26 – 37]




Shin et al. (2017) Overall (141)
F (57)
M (84)
38 [31 – 47]
32 [21 – 44]




Ehgoetz et al. (2018) Overall (221) 
F   (87)
M (134)
42 [35 – 48]
41 [32 – 52]




Contreras et al. (2012) Overall (160)
F (88)
M (72)
44 [37 – 52]
34 [25 – 44]




Ou et al. (2014) Overall (474)
F (217)
M (257)
47 [42 – 51]
48 [41 – 55]




Amboni et al. (2015) Overall (593)
F (238)
M (355)
55 [51 – 59]
58 [52 – 64]




Lamber et al. (1997) Overall (100)
F (30)
M (70)
60 [50 – 69]
70 [52 – 83]




Hall et al. (2015) Overall (389)
F (155)
M (234)
62 [57 – 67]
64 [56 – 71]




Sawada et al. (2019) Overall (229)
F (136)
M (84)
62 [56 – 68]
59 [50 – 67]




Choi et al. (2019) Overall (157)
F (92)
M (65)
71 [63 – 77]
66 [56 – 75]




Rahman et al. (2008) Overall (130)
F (46)
M (84)
72 [64 – 79]
72 [57 – 83]







43 [33 – 53]
42 [31 – 52]
44 [34 – 54]
100.00
0 20 40 60 80 100
Fig. 2  Forest plot of pooled estimates of overall and sex-specific prevalence of freezing of gait in Parkinson’s Disease. F female, M male, LCI 
lower limit of 95% confidence interval, UCI upper limit of 95% confidence interval
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Our results show that the sex distribution in recent 
intervention trials targeting FOG in PD is skewed towards 
men by nearly 20%. There are several explanations for this 
observed difference. First, PD is slightly more prevalent in 
men compared to women, but this cannot fully explain the 
difference in inclusion of men and women in FOG trials. 
In 2016, approximately 6.1 million individuals worldwide 
had PD, of whom 2.9 million (47.5%) were women and 3.2 
million (52.5%) were men [21]. While the age-standardized 
prevalence of PD is higher in men [21], the lifetime risk of 
developing PD is 4.4% for men and 3.7% for women [22]. 
The sex difference we observed in FOG intervention stud-
ies was much greater. Second, women might be less likely 
to be invited to participate in FOG trials, because they may 
be underrepresented in specialized clinics, which generally 
initiate such investigations [23]. According to a retrospective 
observational study investigating the predictors of specialist 
care utilization, women are less likely to receive neurologist 
care compared to men [24]. Third, women may theoretically 
be less inclined to participate in FOG trials, because they 
might cope differently with their disease [25]. For example, 
women could be better at self-management, and therefore 
less likely to seek neurology care. Fourth, women are more 
likely to experience depression and anxiety [26], which 
may negatively affect both their interest to partake in clini-
cal trials, as well as their chances to fulfil fit the inclusion 
criteria. The latter notion could explain why the observed 
sex gap in FOG research is considerably larger than what 
was previously noted for PD research as a whole (20% gap 
in FOG research versus 7% in general PD research) [27], 
since depression and anxiety are both factors associated with 
FOG [6, 7]. Finally, regardless of disease-specific reasons, 
underrepresentation of women in clinical trials appears to be 
a generic challenge, which is increasingly recognized across 
other fields of clinical research as well, including cardiology 
and oncology [28, 29]. A systematic search of nine promi-
nent medical journals regarding randomized controlled trials 
concluded that the median enrollment of women in the 56 
included studies was a mere 37% [30].
As an incidental finding, we found that the inclusion of 
women in trials differed between study regions. Consistent 
with a previous study on sex distribution in PD clinical trials, 
studies conducted in Asia included relatively more women 
compared to studies conducted in Europe or North America 
[27]. Examining whether e.g. potential cultural differences 
in gender roles contribute to this difference in female recruit-
ment is an interesting topic for further investigation.
There are some precautions to take into account when 
interpreting the results of the present study. First, this review 
may not be exhaustive due to the limitations of the search 
strategy. Second, most of the included observational stud-
ies identified FOG through self-reported questionnaires. The 
question therefore remains whether possible differences in 
the prevalence of FOG were masked by differences in the 
way men and women might experience and report their 
motor symptoms. Future work should therefore also focus 
on patients with FOG that is objectively verified by an expe-
rienced examiner. Additionally, cognitive status should be 
taken into account.
The present finding that sex is not a predictor of FOG 
could aid clinicians in counselling persons with PD about 
FOG. Our findings also raise the question whether results 
from PD trials can be fully extrapolated to women with 
PD, as women were underrepresented [27]. Future studies 
may establish the exact impact of this sex data gap, e.g. 
by investigating whether sex differences affect the efficacy 
of different FOG interventions. Most importantly, a global 
effort must be undertaken to include a more representative 
proportion of women into future clinical trials.



















Fig. 3  Overall sex distribution (%) in intervention studies on freez-
ing of gait published in the last five years, stratified per geographical 
location. Due to the limited amount of studies performed in the Mid-
dle East (n = 2), the Pacific (n = 2), South America (n = 3), and inter-
continental collaborations (n = 2), these are not presented as separate 
subcategories. They are represented in the ‘Overall’ category. All 
nine studies concerned were male-predominant
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